Biomarkers for prognosis and treatment selection in advanced bladder cancer patients

Current Opinion in Urology

Volumn 21, Issue 5, 2011, Pages 420-427

  Ru, Yuanbin ^a   Dancik, Garrett M ^a   Theodorescu, Dan ^a,b,c  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Advanced bladder cancer; biomarker; prognosis; treatment selection

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; BRCA1 PROTEIN; CADHERIN; CYCLIN D1; CYCLIN D2; CYCLIN D3; CYCLOOXYGENASE 2 INHIBITOR; DNA; ERLOTINIB; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GALECTIN 3; HUMAN 8 OXOGUANINE DNA GLYCOSYLASE ONE; MICRORNA; MRE11 PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; NERVE CELL ADHESION MOLECULE; PACLITAXEL; PROTEIN; PROTEIN P53; RNA; RTOG 0524; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TRASTUZUMAB; UNCLASSIFIED DRUG; UVOMORULIN;

ADVANCED CANCER; BLADDER CANCER; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CHEMORADIOTHERAPY; CYSTECTOMY; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; ONCOGENE C MYC; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; WESTERN BLOTTING;

EPIGENOMICS; HUMANS; NEOPLASM INVASIVENESS; PHARMACOGENETICS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 80051709556     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32834956d6     Document Type: Review

References (57)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Botteman MF, Pashos CL, Redaelli A, et al. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003;21:1315-1330. (Pubitemid 38041357)
3. McConkey DJ, Lee S, Choi W, et al. Molecular genetics of bladder cancer: emerging mechanisms of tumor initiation and progression. Urol Oncol 2010;28:429-440.
4. Jacobs BL, Lee CT, Montie JE. Bladder cancer in 2010: how far have we come? CA Cancer J Clin 2010;60:244-272.
5. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
6. Feifer AH, Taylor JM, Tarin TV, Herr HW. Maximizing cure for muscle-invasive bladder cancer: integration of surgery and chemotherapy. Eur Urol 2011;56:978-984.
7. Stenzl A, Cowan NC, De Santis M, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011;59:1009-1018.
8. Proctor I, Stoeber K, Williams GH. Biomarkers in bladder cancer. Histopathology 2010;57:1-13.
9. Van Tilborg AA, Bangma CH, Zwarthoff EC. Bladder cancer biomarkers and their role in surveillance and screening. Int J Urol 2009;16:23-30.
10. Lintula S, Hotakainen K. Developing biomarkers for improved diagnosis and treatment outcome monitoring of bladder cancer. Expert Opin Biol Ther 2010;10:1169-1180.
11. Bryan RT, Zeegers MP, James ND, et al. Biomarkersin bladder cancer. BJU Int 2010;105:608-613.
12. Ha YS, Yan C, Kim IY, et al. Tissue hOGG1 genotype predicts bladder cancer prognosis: a novel approach using a peptide nucleic acid clamping method. Ann Surg Oncol 2011;18:1775-1781.
13. Kim EJ, Yan C, Ha YS, et al. Analysis of hOGG1 genotype as a prognostic marker for muscle invasive bladder cancer: a novel approach using peptide nucleic acid-mediated, real-time PCR clamping. Urol Oncol 2010; doi:10.1016/j.urolonc.2010.07.008.
14. Wallerand H, Cai Y, Wainberg ZA, et al. Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines. Urol Oncol 2010;28:180-188.
15. Jager T, Becker M, Eisenhardt A, et al. The prognostic value of cadherin switch in bladder cancer. Oncol Rep 2010;23:1125-1132.
16. Canesin G, Gonzalez-Peramato P, Palou J, et al. Galectin-3 expression is associated with bladder cancer progression and clinical outcome. Tumour Biol 2010;31:277-285.
17. Aziz A, Lessard A, Moore K, et al. Improved cancer specific-survival in patients with carcinoma invading bladder muscle expressing cyclo-oxygenase-2. BJU Int 2010; doi:10.1111/j.1464-410X.2010.09909.x.
18. Naruse K, Yamada Y, Nakamura K, et al. Potential of molecular targeted therapy of HER-2 and Cox-2 for invasive transitional cell carcinoma of the urinary bladder. Oncol Rep 2010;23:1577-1583.
19. Youssef RF, Shariat SF, Kapur P, et al. Prognostic value of cyclooxygenase-2 expression in squamous cell carcinoma of the bladder. J Urol 2011;185:1112-1117.
20. Levidou G, Saetta AA, Karlou M, et al. D-type cyclins in superficial and muscleinvasive bladder urothelial carcinoma: correlation with clinicopathological data and prognostic significance. J Cancer Res Clin Oncol 2010;136:1563-1571.
21. Schultz L, Albadine R, Hicks J, et al. Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy. Cancer 2010;116:5517-5526.
22. Mizutani Y, Katsuoka Y, Bonavida B. Prognostic significance of second mitochondria-derived activator of caspase (Smac/DIABLO) expression in bladder cancer and target for therapy. Int J Oncol 2010;37:503-508.
23. Youssef RF, Shariat SF, Kapur P, et al. Expression of cell cycle-related molecular markers in patients treated with radical cystectomy for squamous cell carcinoma of the bladder. Hum Pathol 2011;42:347-355.
24. Shariat SF, Chade DC, Karakiewicz PI, et al. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol 2010;183:68-75. This article demonstrated the advantage of multiple over single biomarkers in cancer prognosis.
25. Shariat SF, Bolenz C, Karakiewicz PI, et al. p53 expression in patients with advanced urothelial cancer of the urinary bladder. BJU Int 2010;105:489-495.
26. Harshman LC, Bepler G, Zheng Z, et al. Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients. BJU Int 2010;106:1805-1811.
27. Smith SC, Baras AS, Dancik G, et al. A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol 2011;12:137-143. One of the few studies that validated gene signatures in a prospective dataset. The study described a 20-gene model to predict risk of node metastasis after cystectomy in bladder cancer patients. The model was developed from two patient cohorts and validated in a third cohort. Patients with predicted high risk are good candidates for neoadjuvant chemotherapy.
28. Jensen JB, Munksgaard PP, Sorensen CM, et al. High expression of karyopherin-alpha2 defines poor prognosis in non-muscle-invasive bladder cancer and in patients with invasive bladder cancer undergoing radical cystectomy. Eur Urol 2011;59:841-848.
29. Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer 2001;1:22-33. (Pubitemid 33741878)
30. Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 2004;4:118-132. (Pubitemid 38198740)
31. Zheng Z, Chen T, Li X, et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007;356:800-808. (Pubitemid 46294612)
32. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 2005;5:713-725.
33. Choudhury A, Nelson LD, Teo MT, et al. MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. Cancer Res 2010;70:7017-7026. The study suggests that MIBC patients with high MRE11 protein levels are likely to benefit more from radical radiotherapy than from cystectomy. The association of high MRE11 expression with good DSS is tested and validated in two separate radiotherapy cohorts but is lacking in a cystectomy cohort. High MRE11 expression associated with an absolute increase of 16% DSS rate in radiotherapy patients over cystectomy patients.
34. Font A, Taron M, Gago JL, et al. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Ann Oncol 2011;22:139-144.
35. Kawashima A, Nakayama M, Kakuta Y, et al. Excision repair crosscomplementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer. Clin Cancer Res 2011;17:2561-2569.
36. Hoffmann AC, Wild P, Leicht C, et al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia 2010;12:628-636.
37. Bellmunt J, Paz-Ares L, Cuello M, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatinbased chemotherapy. Ann Oncol 2007;18:522-528. (Pubitemid 46359633)
38. Kim KH, Do IG, Kim HS, et al. Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy. APMIS 2010;118:941-948.
39. Said N, Smith S, Sanchez-Carbayo M, Theodorescu D. Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer. J Clin Invest 2011;121:132-147. Association of high ET-1 and ETAR expression with decreased DSS was confirmed in multiple patient cohorts. In cancer cells and mouse models, ET-1 and ETAR are essential for metastatic lung colonization but less important in established tumor growth, suggesting inhibitors of ET-1 and ETAR as adjuvant therapeutic agents before metastasis.
40. Gerber DE, Minna JD. ALK inhibition for nonsmall cell lung cancer: from discovery to therapy in record time. Cancer Cell 2010;18:548-551.
41. Kotwal S, Choudhury A, Johnston C, et al. Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center. Int J Radiat Oncol Biol Phys 2008;70:456-463.
42. Rene NJ, Cury FB, Souhami L. Conservative treatment of invasive bladder cancer. Curr Oncol 2009;16:36-47.
43. Lamarche BJ, Orazio NI, Weitzman MD. The MRN complex in doublestrand break repair and telomere maintenance. FEBS Lett 2010;584:3682-3695.
44. Advanced bladder cancer (ABC) meta-analysis collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur Urol 2005;48:202-205.
45. Hussain MH, Wood DP, Bajorin DF, et al. Bladder cancer: narrowing the gap between evidence and practice. J Clin Oncol 2009;27:5680-5684.
46. Sanchez-Ortiz RF, Huang WC, Mick R, et al. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol 2003;169:110-115. (Pubitemid 35461564)
47. Stordal B, Davey R. A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1. Curr Cancer Drug Targets 2009;9:354-365.
48. Titus B, Frierson HF Jr, Conaway M, et al. Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res 2005;65:7320-7327. (Pubitemid 41161264)
49. Herrmann E, Tiemann A, Eltze E, et al. Endothelin-A-receptor antagonism with atrasentan exhibits limited activity on the KU-19-19 bladder cancer cell line in a mouse model. J Cancer Res Clin Oncol 2009;135:1455-1462.
50. Lauss M, Ringner M, Hoglund M. Prediction of stage, grade, and survival in bladder cancer using genome-wide expression data: a validation study. Clin Cancer Res 2010;16:4421-4433. This study found that of six published survival gene signatures, none could be validated in external data, suggesting the importance of independent validation in biomarker discovery.
51. Lee JK, Havaleshko DM, Cho H, et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci USA 2007;104:13086-13091. (Pubitemid 351737597)
52. Williams PD, Cheon S, Havaleshko DM, et al. Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. Cancer Res 2009;69:8302-8309.
53. Smith SC, Havaleshko DM, Moon K, et al. Use of yeast chemigenomics and COXEN informatics in preclinical evaluation of anticancer agents. Neoplasia 2011;13:72-80.
54. Roukos DH. Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharmacogenomics J 2011;11:81-92.
55. Rothman N, Garcia-Closas M, Chatterjee N, et al. A multistage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet 2010;42:978-984.
56. Kim YK, Kim WJ. Epigenetic markers as promising prognosticators for bladder cancer. Int J Urol 2009;16:17-22.
57. Dyrskjot L, Ostenfeld MS, Bramsen JB, et al. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res 2009;69:4851-4860.